YTHDF Inhibitor

DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (K_D: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer.

YTHDF2-IN-1 (Compound CK-75) is a selective YTHDF2 inhibitor (K_d = 26.2 μM). YTHDF2-IN-1 binds to a small hydrophobic pocket on the YTH domain of YTHDF2, disrupting the interaction between YTHDF2 and m⁶A-modified RNA. YTHDF2-IN-1 induces cell cycle arrest and Apoptosis. YTHDF2-IN-1 is applicable to research on chronic myeloid leukemia, colon cancer and choriocarcinoma.

TAE648 is a target protein ligand of PROTAC SK-3-91 (HY-137341) (Ligand for Target Protein for PROTAC). TAE648 can be used for synthesis PROTAC. TAE648 decreases monolayer-cultured SKOV3ip1 cell viability.

SKLB-Y13 is a selective YTHDF1 inhibitor with an IC₅₀ of 0.76 μM and a K_D of 5.097 μM. SKLB-Y13 binds to the Tyr397 and Trp470 residues in the m⁶A-binding pocket of YTHDF1, disrupting the interaction between YTHDF1 and m⁶A-modified mRNA. SKLB-Y13 inhibits cancer cell proliferation and promotes apoptosis. SKLB-Y13 is applicable to breast cancer-related research.

YTH-IN-2 is a YTH domain inhibitor of YTHDC2 with an IC₅₀ of 16.84 μM. YTH-IN-2 can serve as a lead compound for discovering efficient, selective, and cell-active small-molecule inhibitors of YTHDC2.

YTH-IN-1 (compound N-7) is a pan-YTH domain inhibitor with the IC₅₀ values of 39 μM, 34 μM, 35 μM, 48 μM and 30 μM for human YTH^YTHDF1, YTH^YTHDF2, YTH^YTHDF3, YTH^YTHDC1, and YTH^YTHDC2, respectively.

YTHDF3 Human Pre-designed siRNA Set A contains three designed siRNAs for YTHDF3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

YTHDF1 Human Pre-designed siRNA Set A contains three designed siRNAs for YTHDF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

YTHDF2 Human Pre-designed siRNA Set A contains three designed siRNAs for YTHDF2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PROTAC FTO degrader 1 is a Fat Mass and Obesity-associated Protein (FTO) PROTAC degrader. PROTAC FTO degrader 1 selectively degrades FTO depending on VHL E3 ligase and ubiquitin-proteasome system. PROTAC FTO degrader 1 can increase m₆A modifications on mRNAs associated with ribosome biogenesis and promote their YTHDF2-mediated decay. PROTAC FTO degrader 1 can inhibit cancer cells proliferation and induce apoptosis. PROTAC FTO degrader 1 can be used for the research of cancer, such as acute myeloid leukemia (AML).